depression
(moderate)
Asset
serokind™
Gene Targets
10
Pathway
medicinal
IP
pat pending trademark
Status
Phase I Clinical
Next Steps
UK Medical Research Council Neuroscience & Mental Health Grant Award - awaiting decision
Vascular Dementia
Asset
VNDMA
Gene Targets
3
Pathway
medicinal
IP
Patent potential
Status
R&D
Next Steps
Yield Optimisation Feasibility Study
depression
(mild)
Asset
serotonin precursor
Gene Targets
2
Pathway
consumer
IP
data
Status
In-Market
Anhedonia
Asset
dopamine precursor
Gene Targets
3
Pathway
consumer
IP
data
Status
In-Market
Next Steps
In-market gene cluster to disease severity analysis
Memory
Asset
acetylcholine precursor
Gene Targets
5
Pathway
consumer
IP
data
Status
In-Market
Next Steps
longitudinal intervention efficacy data.
Cognition
Asset
tyrosine
Gene Targets
1
Pathway
consumer
IP
data
Status
In-Market
Alzheimer's dementia
Asset
Docosahexaenoic Acid
Gene Targets
6
Pathway
consumer
IP
data
Status
In-Market
Mild Cognitive Impairment
Asset
Blueberry Protect™
Gene Targets
5
Pathway
consumer
IP
data + trademark
Status
Market Ready
Next Steps
launch products
Aged-related Cognitive Fatigue
(Fatigability)
Asset
brain cell fuel™
Gene Targets
8
Pathway
consumer
IP
data + trademark
Status
Market Ready
Next Steps
In-market gene cluster to disease severity analysis
Alertness
Asset
Beyond Caffeine™
Gene Targets
3
Pathway
consumer
IP
data + trademark
Status
Market Ready (US Only)
Next Steps
longitudinal intervention efficacy data.
Sleep
Asset
Sleep Easy™
Gene Targets
6
Pathway
consumer
IP
data + trademark
Status
Market Ready (US Only)
Built with v0